Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,660 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Transplant Clear all
Terminated Phase 2 Interventional Results available

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

NCT03617445
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
FMT oral capsule, Oral Vancomycin, FMT oral placebo, Oral Vancomycin placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 22, 2026, 5:36 AM EDT
Recruiting Phase 1 Interventional

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

NCT06287944
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Daratumumab, Echocardiography, Fludarabine, Hematopoietic Cell Transplantation, Indium In 111-DOTA-Daratumumab, Melphalan, Multigated Acquisition Scan, Radionuclide Imaging, Single Photon Emission Computed Tomography, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 22, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test

NCT02790437
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
IdeS, Kidney transplantation
Drug · Procedure
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 22, 2026, 5:36 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS

NCT03699475
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
rivogenlecleucel, rimiducid, Cyclophosphamide, haplo-HSCT
Biological · Drug · Procedure
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
12 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 22, 2026, 5:36 AM EDT
Completed Not applicable Interventional

iChoose Decision Kidney Aid for End-Stage Renal Disease Patients

NCT02235571
View directory record Official record
Conditions
End-Stage Kidney Disease, Kidney Failure, Chronic, Kidney Transplantation
Interventions
iChoose Kidney Decision Aid
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 22, 2026, 5:36 AM EDT
Withdrawn Phase 2 Interventional

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

NCT05293509
View directory record Official record
Conditions
Stem Cell Transplantation
Interventions
Fludarabine, Dexamethasone, Cyclophosphamide, Bortezomib, Rituximab, Busulfan, Cyclophosphamide (Cy), Tacrolimus (or cyclosporine), Mycophenolate mofetil (MMF), Rabbit ATG
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 5:36 AM EDT
Terminated Not applicable Interventional Results available

Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease After Donor Stem Cell Transplant

NCT02109809
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
total nodal irradiation, laboratory biomarker analysis, questionnaire administration
Radiation · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2018 · Synced Oct 22, 2026, 5:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease

NCT01288053
View directory record Official record
Conditions
Crohn's Disease
Interventions
Allogeneic Stem Cell Therapy
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 22, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional

Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation

NCT01421212
View directory record Official record
Conditions
Hepatitis B Virus Associated Liver Disease
Interventions
Hepatitis B Immune Globulin (Boca HBVIg)
Biological
Lead sponsor
Biotest Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
11
States / cities
San Francisco, California • Gainesville, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 22, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

NCT03202628
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pomalidomide
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 5:36 AM EDT
Not yet recruiting Not applicable Interventional

Technology-enabled Social Network Intervention to Increase Live Donor Kidney Transplantation

NCT07072767
View directory record Official record
Conditions
End-Stage Renal Disease, Chronic Kidney Diseases, Kidney Transplant, Living Kidney Donor
Interventions
Digital education outreach intervention for kidney transplant access and human guide, Digital education outreach intervention for kidney transplant access only (unguided)
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 5:36 AM EDT
Not listed No phase listed Observational

Donor Outcomes Following Hand-Assisted and Robotic Living Donor Nephrectomy: a Retrospective Review

NCT04182607
View directory record Official record
Conditions
Transplant, Kidney Diseases
Interventions
kidney transplant
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 22, 2026, 5:36 AM EDT
Terminated Not applicable Interventional Results available

Busulfan and Cyclophosphamide Followed By ALLO BMT

NCT01685411
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 44 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 22, 2026, 5:36 AM EDT
Recruiting Phase 1 Interventional

Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant

NCT05849207
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Cyclophosphamide
Drug
Lead sponsor
Ronald Paquette
Other
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 22, 2026, 5:36 AM EDT
Completed No phase listed Observational

Study of the Complications Associated With Certain Stem Cell Transplants

NCT01919099
View directory record Official record
Conditions
Post-Transplant Infections, Post-Transplant Renal Insufficiency, Post-Transplant Pulmonary Complications
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 22, 2026, 5:36 AM EDT
Completed No phase listed Observational

Evidence Based Evaluation and Acceptance of Donor Hearts for Transplantation

NCT02376387
View directory record Official record
Conditions
Heart Transplantation
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
4,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • Oakland, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 22, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional Results available

Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation

NCT01517984
View directory record Official record
Conditions
Kidney Transplant Recipients
Interventions
Tacrolimus (CNI) Withdrawal, Standard Immunosuppressive Therapy
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 22, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

NCT00006184
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide, Cyclosporine, Doxorubicin hydrochloride, Etoposide, Fludarabine phosphate, Prednisone, Vincristine Sulfate, Methotrexate, GMCSF (granulocyte macrophage colony stimulating factor), GCSF (granulocyte colony stimulating factor)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 22, 2026, 5:36 AM EDT
Completed Phase 3 Interventional

Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

NCT03363945
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
MDR-101
Biological
Lead sponsor
Medeor Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Loma Linda, California • Los Angeles, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 22, 2026, 5:36 AM EDT
Active, not recruiting No phase listed Observational

Delirium in Children Undergoing Stem Cell Transplantation

NCT04937400
View directory record Official record
Conditions
Stem Cell Transplant Complications, Delirium
Interventions
Daily screening for delirium
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
Up to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 22, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

A Pilot Study Investigating the Clinical Use of Tissue Engineered Vascular Grafts in Congenital Heart Surgery

NCT01034007
View directory record Official record
Conditions
Single Ventricle Cardiac Anomaly
Interventions
Tissue Engineered Vascular Grafts
Combination Product
Lead sponsor
Christopher Breuer
Other
Eligibility
1 Year to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 22, 2026, 5:36 AM EDT
Completed Not applicable Interventional

Teen Adherence in KidnEy Transplant Improving Tracking To Optimize Outcomes - Stage 3

NCT04288271
View directory record Official record
Conditions
Medication Adherence, Kidney Transplantation
Interventions
Adherence Intervention, Healthy living education intervention
Behavioral · Other
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
12 Years to 24 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 22, 2026, 5:36 AM EDT
Withdrawn No phase listed Observational

Split-Thickness Skin Graft Donor Site Wound Healing Study

NCT00392301
View directory record Official record
Conditions
Split-thickness Skin Graft Donor Sites
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 22, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD

NCT02614612
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Itacitinib (200 mg), Itacitinib (300 mg), prednisone or methylprednisolone (corticosteroids)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 22, 2026, 5:36 AM EDT